Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amifostine + cyclophosphamide + doxorubicin + paclitaxel
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A high-dose chemotherapy combination regimen consisting of amifostine, cyclophosphamide, doxorubicin, and paclitaxel, often used with peripheral stem cell rescue. Amifostine serves as a cytoprotective agent to protect normal cells from chemotherapy side effects, while the other three components target cancer cells through different mechanisms. This combination has been studied primarily in high-risk breast cancer.
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on amifostine + cyclophosphamide + doxorubicin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amifostine + cyclophosphamide + doxorubicin + paclitaxel.